Adding a Third Drug to Diabetes Treatment

antihypoglycemic agent, metformin-plus-sulfonylurea therapy, Universidade Federal do Rio Grande do Sul, Federal University of Rio Grande do Sul, acarbose, thiazolidinediones, glucagon-like peptide-1 agonists, GLP-1, dipeptidyl peptidase-4 inhibitors, DPP-4, insulin antihypoglycemic agent, metformin-plus-sulfonylurea therapy, Universidade Federal do Rio Grande do Sul, Federal University of Rio Grande do Sul, acarbose, thiazolidinediones, glucagon-like peptide-1 agonists, GLP-1, dipeptidyl peptidase-4 inhibitors, DPP-4, insulin

antihypoglycemic agent, metformin-plus-sulfonylurea therapy, Universidade Federal do Rio Grande do Sul, Federal University of Rio Grande do Sul, acarbose, thiazolidinediones, glucagon-like peptide-1 agonists, GLP-1, dipeptidyl peptidase-4 inhibitors, DPP-4, insulin antihypoglycemic agent, metformin-plus-sulfonylurea therapy, Universidade Federal do Rio Grande do Sul, Federal University of Rio Grande do Sul, acarbose, thiazolidinediones, glucagon-like peptide-1 agonists, GLP-1, dipeptidyl peptidase-4 inhibitors, DPP-4, insulin

antihypoglycemic agent, metformin-plus-sulfonylurea therapy, Universidade Federal do Rio Grande do Sul, Federal University of Rio Grande do Sul, acarbose, thiazolidinediones, glucagon-like peptide-1 agonists, GLP-1, dipeptidyl peptidase-4 inhibitors, DPP-4, insulin antihypoglycemic agent, metformin-plus-sulfonylurea therapy, Universidade Federal do Rio Grande do Sul, Federal University of Rio Grande do Sul, acarbose, thiazolidinediones, glucagon-like peptide-1 agonists, GLP-1, dipeptidyl peptidase-4 inhibitors, DPP-4, insulin